X-linked hypophosphatemic rickets: Diagnosis in adult and paucisymptomatic form

Whyte, 1996, X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children, J Clin Endocrinol Metab, 81, 4075 Yuan, 2008, Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia, J Clin Invest, 118, 722 Friedman, 1993, Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia, J Clin Endocrinol Metab, 76, 839 Lamb, 2018, Burosumab: first global approval, Drugs, 78, 707, 10.1007/s40265-018-0905-7 FDA News Release: FDA approves first therapy for rare inherited form of rickets, X-linked hypophosphatemia. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604810.htm [accessed 25.05.18]. Imel, 2019, Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial, Lancet, 293, 2416, 10.1016/S0140-6736(19)30654-3 Portale, 2019, Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period, Calcif Tissue Int, 105, 271, 10.1007/s00223-019-00568-3